PRELUDE THERAPEUTICS INC (PRLD) Spending and interest coverage
- R&D / revenue · 12 months: Value 309.63%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 36.99%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 309.63% | Research and development expense / revenue. Period ending 2026-06-30. $69.43M ÷ $22.42M × 100 ≈ 309.63% |
| Stock-based compensation / revenue · 12 months | 36.99% | Share-based compensation / revenue. Period ending 2026-06-30. $8.29M ÷ $22.42M × 100 ≈ 36.99% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 69.43M USD | Research and Development Expense |
| Revenue | 22.42M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 8.29M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -67.40M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $69.43M | $22.42M | $8.29M | $-67.40M | (m) | 309.63% | 36.99% | (m) | (m) |
| 2026-03-31 | $79.08M | $16.72M | $10.08M | $-84.14M | (m) | 473.00% | 60.29% | (m) | (m) |
| 2025-12-31 | $94.30M | $12.14M | $11.91M | $-104.57M | (m) | 776.77% | 98.13% | (m) | (m) |
| 2025-09-30 | $107.93M | $10.50M | $13.84M | $-121.05M | (m) | 1027.89% | 131.84% | (m) | (m) |
| 2025-06-30 | $115.68M | (m) | $17.35M | $-135.01M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $119.40M | (m) | $19.63M | $-139.98M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $118.00M | $7.00M | $21.34M | $-139.71M | (m) | 1685.64% | 304.93% | (m) | (m) |
| 2024-09-30 | $116.71M | (m) | $23.48M | $-143.26M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $113.51M | (m) | $24.27M | $-142.27M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $108.97M | (m) | $24.91M | $-137.50M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $103.39M | (m) | $25.62M | $-132.28M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $98.93M | (m) | $25.55M | $-128.28M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $95.56M | (m) | $25.28M | $-125.30M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $91.90M | (m) | $24.57M | $-122.37M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $92.89M | (m) | $25.14M | $-123.54M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $92.20M | (m) | $25.07M | $-123.17M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $92.03M | (m) | $25.66M | $-123.59M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $93.13M | (m) | $23.87M | $-122.06M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $86.78M | (m) | $20.93M | $-113.73M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $76.17M | (m) | $18.28M | $-100.17M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $68.74M | (m) | $12.72M | $-87.48M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $56.11M | (m) | $9.11M | $-70.99M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $48.18M | (m) | $5.58M | $-58.76M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $24.28M | (m) | $846.00K | $-28.11M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |